Myeloproliferative neoplasms and endothelial progenitor cells.
10.7534/j.issn.1009-2137.2015.01.051
- Author:
Xue HAN
1
;
Fang WANG
1
;
Ye CHEN
2
Author Information
1. Department of Hematology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China.
2. Department of Hematology, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, China. E-mail:cycy111@sina.com.
- Publication Type:Journal Article
- MeSH:
Endothelial Cells;
Endothelial Progenitor Cells;
Humans;
Janus Kinase 2;
Mutation;
Myeloproliferative Disorders
- From:
Journal of Experimental Hematology
2015;23(1):270-273
- CountryChina
- Language:Chinese
-
Abstract:
JAK2V617F is a novel oncogene involved in myeloproliferative neoplasms (MPN) and closely related to its vascular complications. Recent researches found the vascular endothelial injury in patients with MPN. It is increasingly being recognized that endothelial cells and endothelial progenitor cells (EPC) play an important role in MPN. Here, the pathogenesis of the EPC JAK2V617F mutation and peripheral blood EPC counts in patients with MPN or with vascular complications are reviewed.
